Literature DB >> 22124121

Overexpression of the Ctla-4 isoform lacking exons 2 and 3 causes autoimmunity.

Sue M Liu1, Andrew P R Sutherland, Zheng Zhang, Daniel B Rainbow, Francisco J Quintana, Alison M Paterson, Arlene H Sharpe, Mohamed Oukka, Linda S Wicker, Vijay K Kuchroo.   

Abstract

CTLA-4 is a potent inhibitor of T cell activation, primarily upon binding to its costimulatory ligands (B7.1 and B7.2) expressed on APCs. However, variants of CTLA-4 can also function independently of B7 molecules. 1/4CTLA-4 is a highly conserved isoform encoded by exons 1 and 4 of the Ctla4 gene that lacks the ligand-binding and the transmembrane domains, and as yet, its function is not known. To investigate the function of 1/4CTLA-4, we generated transgenic (Tg) mice overexpressing this variant. Cytokine production by 1/4CTLA-4 Tg T cells was elevated compared with wild type T cells. The frequency of CD44(high) memory T cells in 1/4CTLA-4 Tg mice was increased, and as the mice aged, the frequency further increased. 1/4CTLA-4 Tg mice >1 y old had increased expression of T cell activation markers and developed spontaneous autoimmunity, including elevated production of autoantibodies. In contrast with young 1/4CTLA-4 Tg mice, aged 1/4CTLA-4 Tg mice had elevated frequencies of Foxp3(+) regulatory T cells, but the regulatory T cells from these mice were not able to inhibit colitis development. Collectively, these data suggest that the function of the 1/4CTLA-4 isoform is distinct from that of CTLA-4 in that it enhances T cell activation and promotes autoimmunity rather than inhibiting immune responses.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22124121      PMCID: PMC3245861          DOI: 10.4049/jimmunol.1102042

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  23 in total

1.  B7-independent inhibition of T cells by CTLA-4.

Authors:  Shunsuke Chikuma; Abul K Abbas; Jeffrey A Bluestone
Journal:  J Immunol       Date:  2005-07-01       Impact factor: 5.422

2.  Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells.

Authors:  Estelle Bettelli; Yijun Carrier; Wenda Gao; Thomas Korn; Terry B Strom; Mohamed Oukka; Howard L Weiner; Vijay K Kuchroo
Journal:  Nature       Date:  2006-04-30       Impact factor: 49.962

3.  Induction of peripheral T cell tolerance in vivo requires CTLA-4 engagement.

Authors:  V L Perez; L Van Parijs; A Biuckians; X X Zheng; T B Strom; A K Abbas
Journal:  Immunity       Date:  1997-04       Impact factor: 31.745

4.  Blockade of CTLA-4 on CD4+CD25+ regulatory T cells abrogates their function in vivo.

Authors:  Simon Read; Rebecca Greenwald; Ana Izcue; Nicholas Robinson; Didier Mandelbrot; Loise Francisco; Arlene H Sharpe; Fiona Powrie
Journal:  J Immunol       Date:  2006-10-01       Impact factor: 5.422

5.  Regulation of CTLA-4 expression during T cell activation.

Authors:  D Perkins; Z Wang; C Donovan; H He; D Mark; G Guan; Y Wang; T Walunas; J Bluestone; J Listman; P W Finn
Journal:  J Immunol       Date:  1996-06-01       Impact factor: 5.422

6.  Genetic evidence that the differential expression of the ligand-independent isoform of CTLA-4 is the molecular basis of the Idd5.1 type 1 diabetes region in nonobese diabetic mice.

Authors:  Manabu Araki; Denise Chung; Sue Liu; Daniel B Rainbow; Giselle Chamberlain; Valerie Garner; Kara M D Hunter; Lalitha Vijayakrishnan; Laurence B Peterson; Mohamed Oukka; Arlene H Sharpe; Raymond Sobel; Vijay K Kuchroo; Linda S Wicker
Journal:  J Immunol       Date:  2009-09-25       Impact factor: 5.422

7.  CTLA-4 control over Foxp3+ regulatory T cell function.

Authors:  Kajsa Wing; Yasushi Onishi; Paz Prieto-Martin; Tomoyuki Yamaguchi; Makoto Miyara; Zoltan Fehervari; Takashi Nomura; Shimon Sakaguchi
Journal:  Science       Date:  2008-10-10       Impact factor: 47.728

8.  Enhancement of antitumor immunity by CTLA-4 blockade.

Authors:  D R Leach; M F Krummel; J P Allison
Journal:  Science       Date:  1996-03-22       Impact factor: 47.728

Review 9.  A molecular perspective of CTLA-4 function.

Authors:  Wendy A Teft; Mark G Kirchhof; Joaquín Madrenas
Journal:  Annu Rev Immunol       Date:  2006       Impact factor: 28.527

10.  B7-1 or B7-2 is required to produce the lymphoproliferative phenotype in mice lacking cytotoxic T lymphocyte-associated antigen 4 (CTLA-4).

Authors:  D A Mandelbrot; A J McAdam; A H Sharpe
Journal:  J Exp Med       Date:  1999-01-18       Impact factor: 14.307

View more
  15 in total

Review 1.  Immune checkpoints in central nervous system autoimmunity.

Authors:  Nicole Joller; Anneli Peters; Ana C Anderson; Vijay K Kuchroo
Journal:  Immunol Rev       Date:  2012-07       Impact factor: 12.988

2.  Kidney injuries related to ipilimumab.

Authors:  Hassane Izzedine; Victor Gueutin; Chems Gharbi; Christine Mateus; Caroline Robert; Emilie Routier; Marina Thomas; Alain Baumelou; Philippe Rouvier
Journal:  Invest New Drugs       Date:  2014-04-01       Impact factor: 3.850

Review 3.  RNA Splicing and Disease: Animal Models to Therapies.

Authors:  Matías Montes; Brianne L Sanford; Daniel F Comiskey; Dawn S Chandler
Journal:  Trends Genet       Date:  2018-11-19       Impact factor: 11.639

4.  Potentiating functional antigen-specific CD8⁺ T cell immunity by a novel PD1 isoform-based fusion DNA vaccine.

Authors:  Jingying Zhou; Allen Kl Cheung; Henggui Liu; Zhiwu Tan; Xian Tang; Yuanxi Kang; Yanhua Du; Haibo Wang; Li Liu; Zhiwei Chen
Journal:  Mol Ther       Date:  2013-04-16       Impact factor: 11.454

Review 5.  Coinhibitory Pathways in the B7-CD28 Ligand-Receptor Family.

Authors:  Frank A Schildberg; Sarah R Klein; Gordon J Freeman; Arlene H Sharpe
Journal:  Immunity       Date:  2016-05-17       Impact factor: 31.745

6.  Brief report: increased expression of a short splice variant of CTLA-4 exacerbates lupus in MRL/lpr mice.

Authors:  Kunihiro Ichinose; Zheng Zhang; Tomohiro Koga; Yuang-Taung Juang; Katalin Kis-Tóth; Arlene H Sharpe; Vijay Kuchroo; José C Crispín; George C Tsokos
Journal:  Arthritis Rheum       Date:  2013-03

7.  Opposing effects of CTLA4 insufficiency on regulatory versus conventional T cells in autoimmunity converge on effector memory in target tissue.

Authors:  Priyadharshini Devarajan; Jason Miska; Jen Bon Lui; Dominika Swieboda; Zhibin Chen
Journal:  J Immunol       Date:  2014-09-22       Impact factor: 5.422

8.  Deletion of CTLA-4 on regulatory T cells during adulthood leads to resistance to autoimmunity.

Authors:  Alison M Paterson; Scott B Lovitch; Peter T Sage; Vikram R Juneja; Youjin Lee; Justin D Trombley; Carolina V Arancibia-Cárcamo; Raymond A Sobel; Alexander Y Rudensky; Vijay K Kuchroo; Gordon J Freeman; Arlene H Sharpe
Journal:  J Exp Med       Date:  2015-09-14       Impact factor: 14.307

9.  dNP2 is a blood-brain barrier-permeable peptide enabling ctCTLA-4 protein delivery to ameliorate experimental autoimmune encephalomyelitis.

Authors:  Sangho Lim; Won-Ju Kim; Yeon-Ho Kim; Sohee Lee; Ja-Hyun Koo; Jung-Ah Lee; Heeseok Yoon; Do-Hyun Kim; Hong-Jai Park; Hye-Mi Kim; Hong-Gyun Lee; Ji Yun Kim; Jae-Ung Lee; Jae Hun Shin; Lark Kyun Kim; Junsang Doh; Hongtae Kim; Sang-Kyou Lee; Alfred L M Bothwell; Minah Suh; Je-Min Choi
Journal:  Nat Commun       Date:  2015-09-15       Impact factor: 14.919

10.  The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network.

Authors:  Caroline J Voskens; Simone M Goldinger; Carmen Loquai; Caroline Robert; Katharina C Kaehler; Carola Berking; Tanja Bergmann; Clemens L Bockmeyer; Thomas Eigentler; Michael Fluck; Claus Garbe; Ralf Gutzmer; Stephan Grabbe; Axel Hauschild; Rüdiger Hein; Gheorghe Hundorfean; Armin Justich; Ullrich Keller; Christina Klein; Christine Mateus; Peter Mohr; Sylvie Paetzold; Imke Satzger; Dirk Schadendorf; Marc Schlaeppi; Gerold Schuler; Beatrice Schuler-Thurner; Uwe Trefzer; Jens Ulrich; Julia Vaubel; Roger von Moos; Patrik Weder; Tabea Wilhelm; Daniela Göppner; Reinhard Dummer; Lucie M Heinzerling
Journal:  PLoS One       Date:  2013-01-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.